HopeStage
Back to all studies
CompletedNCT03947827

Minocycline Added to Care for Treatment-Resistant Depression

About this titleRead the official source — NCT03947827

This study assessed depression symptoms.

Medication studyAges 18–80Canada
The study in practice

Understand this study

What did researchers investigate?

This study assessed depression symptoms.

Who was this study for?

Listed age limits: 18 years to 80 years.

Listed locations
TorontoSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: February 1, 2020
Recruitment status
Completed
Enrollment listed in the registry
76
Sponsor
Centre for Addiction and Mental Health
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada
Age range
From 18 Years to 80 Years
Official registry ID
NCT03947827
Official title
Show the full official title

Minocycline as Adjunctive Treatment for Treatment Resistant Depression: a Double Blind, Placebo-controlled, Randomized Trial

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study assessed depression symptoms.

Who is behind this study?

The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Minocycline.

Who was this study for?

Listed age limits: 18 years to 80 years.

Want to explore more studies?

Explore studies